The Nasdaq biotechnology company Enlivex Therapeutics (ENLV) announced a PIPE financing of $212 million, with part of the funds invested in RAIN Token, while accepting USDT stablecoin. This is not only a capital injection but also symbolizes traditional enterprises stepping into Web3, exploring strategic opportunities in prediction markets and crypto assets.
The innovative form of PIPE fundraising.
Enlivex Therapeutics (ENLV) recently announced a significant financing plan: issuing 212 million shares at $1 per share through a PIPE (Private Investment in Public Equity), with completion expected on November 25. The uniqueness of this fundraising lies in the fact that funding can be accepted in USD and USDT stablecoins, breaking the traditional biotech financing model limited to fiat currencies and opening new pathways for companies to venture into the crypto space.
The strategic significance of a major布局 of RAIN Token
Enlivex plans to invest a significant portion of its fundraising into RAIN Token, which is the core asset of the Rain Protocol in the Arbitrum ecosystem, focusing on decentralized prediction and options markets. This move has multiple implications: the biotech industry is recognizing the prediction market as a formal investment target for the first time; traditional enterprises are significantly increasing their acceptance of Web3 applications; and it sets a precedent for institutional funds entering the crypto prediction space. This is not just a financial allocation, but also represents Enlivex’s active exploration of digital financial tools.
Balancing core business research and cryptocurrency investment
Although the cross-border Web3 has attracted much attention, Enlivex emphasizes that the fundraising is mainly used for advancing its core business. Some funds will continue to support clinical trials of Allocetra therapy, focusing on the research and development of diseases such as sepsis and osteoarthritis. This shows that the company’s strategy is “crypto as a supplement, core business as the main focus,” treating digital assets as a complement for diversified growth rather than a replacement for traditional R&D pathways.
Board Upgrade and International Vision
Enlivex also announced that former Italian Prime Minister Matteo Renzi has joined the board. Renzi’s political and international experience will strengthen the company’s positioning in the EU market, policy lobbying, and global cooperation opportunities. The addition of this heavyweight member not only enhances the corporate image but also injects new momentum into Enlivex’s strategic execution in the intersection of biotechnology and finance.
Summary
Enlivex’s financing strategy symbolizes the traditional biotech industry accelerating into the Web3 wave. By accepting USDT and investing in RAIN tokens, the company not only optimizes its funding sources but also expands the investment potential of prediction markets. This cross-border model, which combines clinical research and digital asset layout, indicates that the industry will present a deep integration of finance, technology, and healthcare in the future, bringing new possibilities to the market.
* The information is not intended to be and does not constitute financial advice or any other recommendation of any sort offered or endorsed by Gate.
